Krystal Biotech (KRYS) Change in Receivables (2023 - 2026)
Krystal Biotech (KRYS) reported Change in Receivables of -$58000.0 for Q1 2026, up 96.1% on a YoY basis from -$29577.2 in Q1 2025, and up 97.67% sequentially from -$2.5 million in Q4 2025.
Krystal Biotech (KRYS) Change in Receivables (2023 - 2026) Analysis & Trends
Krystal Biotech (KRYS) has 4 years of Change in Receivables data on file, last reported at -$58000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables rose 96.1% year-over-year to -$58000.0; the trailing twelve-month figure through Mar 2026 stood at $23.6 million (down 58.53% YoY), and the FY2025 full-year result was $22.1 million, down 64.72% from the prior year.
- Change in Receivables improved to -$58000.0 in Q1 2026, from -$2.5 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $56.8 million in Q2 2024 to a low of -$5.9 million in Q3 2024.
- A 4-year average of $11.5 million and a median of $7.4 million in 2024 frame the typical range for Change in Receivables.
- Across the five-year window, Change in Receivables sank 163.75% in 2024 and surged 401.78% in 2025, its largest moves.
- Tracing KRYS's Change in Receivables over 4 years: stood at $32.7 million in 2023, then slumped by 77.24% to $7.4 million in 2024, then sank by 133.45% to -$2.5 million in 2025, then jumped by 97.67% to -$58000.0 in 2026.
- Business Quant data shows KRYS's Change in Receivables at -$58000.0 in Q1 2026, -$2.5 million in Q4 2025, and $17.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Krystal Biotech | 9.59 Bn | 8.77 Bn | 110.08 Mn | -58,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58,000.00 |
| Mar 31, 2026 | -58,000.00 |
| Dec 31, 2025 | -2.49 Mn |
| Dec 31, 2025 | -2.49 Mn |
| Sep 30, 2025 | 17.92 Mn |
| Sep 30, 2025 | 17.92 Mn |
| Jun 30, 2025 | 8.18 Mn |
| Jun 30, 2025 | 8.18 Mn |
| Mar 31, 2025 | -1.49 Mn |
| Mar 31, 2025 | -1.49 Mn |
| Dec 31, 2024 | 7.45 Mn |
| Dec 31, 2024 | 7.45 Mn |
| Sep 30, 2024 | -5.94 Mn |
| Sep 30, 2024 | -5.94 Mn |
| Jun 30, 2024 | 56.77 Mn |
| Jun 30, 2024 | 56.77 Mn |
| Mar 31, 2024 | 4.43 Mn |
| Mar 31, 2024 | 4.43 Mn |
| Dec 31, 2023 | 32.72 Mn |
| Dec 31, 2023 | 32.72 Mn |